Hutchmed shines in Hong Kong debut, teahouse operator Nayuki drops

Nayuki Holdings

30/06/2021 04:30

** Shares of oncology and immunology drug developer and
maker Hutchmed China Ltd  0013.HK  trade as high as HK$59.80 in
Hong Kong debut, up 49.1% from offer price    
    ** Stock of CK Hutchison  0001.HK  backed biopharmaceutical
firm last up 42.6% from the offer price of HK$40.10 each
    ** U.S. and London-listed Hutchmed  HCM.O  HCM.L  offered
104 mln shares in Hong Kong, raising HK$4.17 bln  ($537.1 mln)
for clinical programs, adding products, and business development
and acquisition  urn:newsml:reuters.com:*:nASA02BTM
    ** Another newcomer, Nayuki Holdings Ltd  2150.HK , which
serves freshly-made tea drinks in China, falls as much as 12.6%
from the IPO price to HK$17.30 on debut
    ** Shares last down 10.8% from the IPO price of HK$19.80
each; the second most actively traded by turnover
    ** Guangdong-based teahouse chain operator sold 257.27 mln
shares in IPO, raising HK$5.09 bln to expand network, boost 
efficiency and supply chain capabilities  urn:newsml:reuters.com:*:nFWN2NZ11A
    ** The Hang Seng Commerce & Industry Index  .HSNC  slips
0.4%, and the consumer goods and services index  .HSCGSI  eases
0.2%
    ** The Hang Seng China Enterprises Index  .HSCE  slides
0.4%, and the benchmark index  .HSI  down 0.3%
($1=7.7644 Hong Kong dollars)

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))